» Articles » PMID: 29050324

Prognostic and Predictive Value of Metastatic Lymph Node Ratio in Stage III Gastric Cancer After D2 Nodal Dissection

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Oct 21
PMID 29050324
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: This study is to evaluate the prognostic and predictive value of metastatic lymph node ratio (MLR) in stage III gastric cancer following radical D2 dissection.

Methods: 87 patients who underwent radical resection with D2 lymphadenectomy were retrospectively evaluated. The median age was 60 with a 2:1 ratio of male/female. Of these 87 patients, 83 underwent total gastrectomy, the remaining 4 underwent subtotal gastrectomy and 57 patients received adjuvant chemotherapy with fluoropyrimidines. Indexes of lymph node involvement and other clinicopathological data were analyzed. Survival was determined by the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.

Results: Median total retrieved lymph node number was 35 (range: 10-104) with median metastatic lymph node amount of eight (range: 0-71). Median survival time was 31.7 months with a 3-year survival rate of 36.4%. Patients were divided into four groups according to MLR: MLR0, 0; MLR1, <0.1; MLR2, 0.1-0.25; MLR3, >0.25. After median follow-up of 31 months, median OS rates of MLR0 to MLR3 were 37.1m, 35.9m, 31.5m and 20.8m, respectively (p=0.013). Median OS rates were significantly different among subgroups: 39.3m and 36.5m were obtained for low subgroups (MLR<0.24) with or without adjuvant chemotherapy, respectively; 22.9m and 12.2m were found in high subgroups (MLR>0.24) with and without chemotherapy, respectively (p=0.002). Finally, MLR constituted an independent prognostic factor in multivariable analysis.

Conclusions: After R0 resection with D2 lymphadenectomy for stage III gastric cancer, MLR constitutes an effective prognostic indicator. Patients with high MLR may benefit the most from adjuvant chemotherapy.

Citing Articles

The relation between ABO blood groups and clinicopathologic characteristics of the patients with gastric adenocarcinomas.

Celik S, Gulap Y, Demir M, Kaymak S, Senocak R Turk J Surg. 2025; 40(3):240-246.

PMID: 39917399 PMC: 11792905. DOI: 10.47717/turkjsurg.2024.6434.


Sarcopenia Affects Systemic and Local Immune System and Impacts Postoperative Outcome in Patients with Extrahepatic Cholangiocarcinoma.

Kitano Y, Yamashita Y, Saito Y, Nakagawa S, Okabe H, Imai K World J Surg. 2019; 43(9):2271-2280.

PMID: 31041559 DOI: 10.1007/s00268-019-05013-y.

References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Harrison J, FIELDING J . Prognostic factors for gastric cancer influencing clinical practice. World J Surg. 1995; 19(4):496-500. DOI: 10.1007/BF00294709. View

3.
Kutlu O, Watchell M, Dissanaike S . Metastatic lymph node ratio successfully predicts prognosis in western gastric cancer patients. Surg Oncol. 2015; 24(2):84-8. DOI: 10.1016/j.suronc.2015.03.001. View

4.
Lee S, Kim H, Son B, Shin J, Yoo C . Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer. World J Surg. 2012; 36(5):1096-1101. DOI: 10.1007/s00268-012-1520-5. View

5.
Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D . The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007; 245(4):543-52. PMC: 1877031. DOI: 10.1097/01.sla.0000250423.43436.e1. View